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The link of chromatin remodeling to both neurodevelopment and cancer has recently been highlighted by the identification of muta-
tions affecting BAF chromatin-remodeling components, such as ARID1B, in individuals with intellectual disability and cancer. However,
the underlying molecular mechanism(s) remains unknown. Here, we show that ARID1B is a repressor of Wnt/b-catenin signaling.
Through whole-transcriptome analysis, we find that in individuals with intellectual disability and ARID1B loss-of-function mutations,
Wnt/b-catenin target genes are upregulated. Using cellular models of low and high Wnt/b-catenin activity, we demonstrate that knock-
down of ARID1B activatesWnt/b-catenin target genes andWnt/b-catenin-dependent transcriptional reporters in a b-catenin-dependent
manner. Reciprocally, forced expression of ARID1B inhibits Wnt/b-catenin signaling downstream of the b-catenin destruction complex.
Both endogenous and exogenous ARID1B associate with b-catenin and repress Wnt/b-catenin-mediated transcription through the BAF
core subunit BRG1. Accordingly, mutations in ARID1B leading to partial or complete deletion of its BRG1-binding domain, as is often
observed in intellectual disability and cancers, compromise association with b-catenin, and the resultant ARID1Bmutant proteins fail to
suppress Wnt/b-catenin signaling. Finally, knockdown of ARID1B in mouse neuroblastoma cells leads to neurite outgrowth through
b-catenin. The data suggest that aberrations in chromatin-remodeling factors, such as ARID1B, might contribute to neurodevelopmental
abnormalities and cancer through deregulation of developmental and oncogenic pathways, such as the Wnt/b-catenin signaling
pathway.Introduction
The human BRG1-associated factors (BAF) chromatin-
remodeling complex (also known as SWI/SNF-A complex)
repositions and alters the structure of nucleosomes, facili-
tating the activation or repression of gene transcription.1
ARID1, also known as BAF250 and hOsa, is the largest sub-
unit of the BAF complex and has two isoforms: ARID1A
and ARID1B.2,3 ARID1B is expressed in the human brain
and in mammalian embryonic stem cells, and ARID1B-
associated BAF complexes are important in the early stages
of murine brain development and essential for the plurip-
otency of mouse embryonic stem cells.4–6 Recent studies
have reported overlapping mutational spectrums in BAF
subunits, including loss-of-function mutations in ARID1B
(MIM: 614556), in both neurodevelopmental disorders,
such as Coffin-Siris syndrome (MIM: 135900), and non-
syndromic intellectual disability (ID [MIM: 614562]), as
well as in numerous cancer entities.7–15 However, the num-
ber of studies addressing the molecular mechanisms by
which ARID1B functions and how its loss-of-function con-
tributes to neurodevelopmental disorders and cancer is
limited. The role of aberrant Wnt/b-catenin signaling in
cancer, particularly colorectal cancer, is well established,
and the pathway has been implicated in neuronal develop-
ment. Increased dosage as well as knockout of b-catenin in
the brain leads to CNS defects.16–19 b-catenin is phosphor-
ylated in the ‘‘b-catenin destruction complex,’’ a multi-pro-
tein complex composed of the adenomatous polyposis coli1Institute of Human Genetics, Friedrich-Alexander-Universita¨t Erlangen-Nu¨rnb
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thase kinase GSK3b, and earmarked for proteosomal degra-
dation. In the presence of Wnt ligands, this destruction
complex is inactivated and b-catenin is stabilized and
subsequently translocates to the nucleus to activate tran-
scription of Wnt target genes.20 Wnt target genes control
a variety of cellular processes, including proliferation, dif-
ferentiation, and pluripotency.21
A connection between the BAF chromatin-remodeling
complex and Wnt/b-catenin signaling was originally iden-
tified by Baker et al., showing that BRG1 interacts with
b-catenin to promote target-gene activation.22 These find-
ings have been supported by subsequent research showing
that BRG1 is required for Wnt/b-catenin-mediated tran-
scriptional activation of target genes and that loss of
BRG1 attenuates aberrant Wnt signaling and prevents
Wnt-dependent tumorigenesis in the murine small intes-
tine.23,24 However, a contrasting view has emerged from
a recent report suggesting that SNF5, another subunit of
the BAF complex and a tumor suppressor, represses Wnt/
b-catenin-mediated gene expression and that loss of
SNF5 leads to activation of Wnt target genes.25 Interest-
ingly, frequent inactivating mutations in ARID1B were
also reported in colorectal cancers driven by aberrant
Wnt/b-catenin signaling, and ARID1B-mutated medullo-
blastomas show activation of the Wnt/b-catenin
pathway.7,26 By using individuals with ID who are
harboring ARID1B loss-of-function mutations as a depar-
ture point and subsequently moving to cellular modelserg, 91054 Erlangen, Germany; 2Institute of Human Genetics, University of
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to study in detail ARID1B’s function, we find that ARID1B
represses Wnt/b-catenin signaling in the nucleus at the
level of b-catenin through a BRG1-dependent mechanism.
Importantly, ARID1B loss-of-function mutants fail to
repress Wnt/b-catenin-mediated transcription and, simi-
larly to knockdown of ARID1B, lead to upregulation of
target genes of the pathway.Materials and Methods
Subjects
The six individuals with ID were described in detail in the previous
study9 (see Figure S1.) The current studywas approved by the insti-
tutional ethical review board of the medical faculty of Erlangen-
Nu¨rnberg University, and informed consent was obtained from
the participants or their legal guardians.
RNA Isolation, cDNA Synthesis, and Quantitative
Real-Time PCR
Total RNA was extracted from untransformed blood lymphocytes
from six ID-affected individuals and twelve control individuals
with the PAXgene Blood System (Becton Dickinson). The RNA
extraction from U2OS, 293T, and HCT116 cells was performed
with an RNeasy Mini Kit and a Qiashredder Kit (QIAGEN). cDNA
was prepared with a Superscript II Reverse Transcriptase Kit
(Invitrogen), according to the manufacturer’s instructions. Ex-
pression levels of genes were analyzed by qRT-PCR with prede-
signed Taqman gene-expression assays (MYC: Hs00153408_m1,
LEF1: Hs01547250_m1, TCF7: Hs00175273_m1, ARID1B:
Hs00368175_m1, and ARID1A: Hs00195664_m1; Life Technolo-
gies) on an ABI 7900HT instrument (Life Technologies). For
normalization of results to the mean, the following endogenous
controls were used: b-actin (huACTB), b-2 microglobulin (huB2M),
acidic ribosomal protein (huPO), and transcription-factor IID
(huTBP) (Applied Biosystems). Expression in the six ID-affected in-
dividualswas normalized relative to the twelve control individuals,
whereas expression in ARID1B siRNA-treated U20S, 293T, and
HCT116 cells was normalized to control siRNA-treated cells. Reac-
tions were performed in four replicates. mRNA levels were
calculated with the DDCt method. The p values for control and
ID-affected individuals and cell lines were calculated with Mann-
Whitney and unpaired Student’s t tests, respectively.
RNA-Seq and Bioinformatic Analysis
RNA were amplified with the Ovation RNA-Seq System V2
(Nugen), according to the manufacturer’s instructions. cDNA
was purified with the MinElute Reaction Cleanup Kit (QIAGEN),
fragmented by ultrasonic shearing with the Covaris S2 System
(Covaris), and was subsequently used for automated library con-
struction on a Beckman Coulter SRIworks platform (Beckman
Coulter). Sequencing was carried out on a SOLID platform (Life
Technologies). The LifeScope analysis suite produced both
absolute read counts and reads per kilobase per million reads
(RPKM) for 24,364 genes for each individual. Primary component
analysis of the RPKM values was performed with Cluster 3.0.27
All subsequent statistical analyses were also performed in R version
2.14.2. Pathway analysis for 452 differentially expressed genes
with an expression change of >2-fold in either direction and a
p value <0.01 was performed with Ingenuity Systems IPA
Software.446 The American Journal of Human Genetics 97, 445–456, SeptembCell Culture, Transfections, and siRNA Sequences
HEK293T cells, human osteosarcoma U2OS cells, and colorectal
cancer cell lines HCT116, DLD1, SW480, and CaCo-2 were grown
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin
at 37C in 10% CO2. For the lymphoblastoid cell lines used in
Figure 2G, lymphocytes were transformed and immortalized
with Epstein-Barr virus and cultured in Roswell Park Memorial
Institute 1640 L-glutamin medium with 20% FCS (Biochrom)
and 100mg/ml cyclosporin. Previously published siRNAs against
GFP, APC, AXIN1, BRG1 (Santa Cruz), and b-catenin, as well as
siRNAs targeting human ARID1B 50-CUCUCUGGUUGCAUCU
GUC-30 (ARID1B) and 50-GCCGAAUUACAAACGCCAUAU-30
(ARID1B2), as well as siRNAs targeting ARID1A 50-CUCAUUG
GUUUCACAAGUC-30 (Thermo Scientific), were transfected with
oligofectamin (Invitrogen).28–31 Plasmids were transfected with
polyethylenimine. Plasmids and siRNAs were co-transfected via
Lipofectamin (Invitrogen).
Molecular Biology, Plasmids, and Mutagenesis
Standard molecular biology methods were used for cloning N-ter-
minal GFP- and Flag-tagged constructs. Luciferase reporters
TOPFlash, FOPFlash, pFR, and 8xDBE, as well as expression plas-
mids for pFA2-c-Jun, RFP FoxO3A, GFP b-catenin, and Flag Axin,
have been described in Dehner et al. and Hadjihannas et al.28,29
T7-tagged ARID1B (T7hOsa2) and Flag-tagged-BRG1 were ob-
tained from Addgene and have been previously described.32 The
mutations in ARID1B were generated by mutagenesis PCR with
50-GCAGAAAGGACTTGATAAGCTTCCTAGAGGATGGGGTCAC
GATG-30 (forward) and 50-CTTATCAAGTCCTTTCTGCACAGC
TATGGCCCTTGCTGCTAG-30 (reverse) primers for ARID1B-2188
and 50-ACCCAAAGGAGTAGCCCAAGCAAGCCAGTAAGTTCGA
CAAGCTGCCA-30 (forward) and 50-CTTGGGCTACTCCTTTGGGT
CTGCAGCGGCGTCCGGGGCAGTCAGAG-30 (reverse) primers
for ARID1B-1777. The sequences of ARID1B plasmids were
confirmed by sequencing as described in Hadjihannas et al.33
TOP/FOPFlash Luciferase-Reporter Assays
Cells transfected with TOP/FOPFlash reporters together with
plasmids for 24 hr or siRNAs for 48 hr were lysed and luciferase
activities were measured on a centro X53 LB 960 microplate
Luminometer. For each experiment, TOP/FOPFlash reporters
with plasmids and/or siRNAs were transfected in duplets together
with an expression plasmid for b-galactosidase (b-gal). After cell
lysis, b-gal expression was determined on an ELISA reader
and used to normalize luciferase activity for transfection effi-
ciency. Transfection efficiency-normalized luciferase values from
TOPFlash and FOPFlash duplets were subsequently averaged and
used to calculate the TOP/FOPFlash ratio. TOP/FOPFlash ratios
from at least three biological replicates were used to determine
SEM and p values, with unpaired Student’s t test, for differences
between transfections referred to in the Results.
Immunofluorescence Staining and Microscopy
Cells on coverslips were fixed in 100% methanol at 20C or 3%
paraformaldehyde at room temperature, permeablized with Triton
X-100, and blocked in DMEM media containing 10% FCS.
Cells were incubated with primary antibodies rabbit polyclonal
anti-ARID1B (Millipore), mouse monoclonal anti-ARID1B
(Abcam), rabbit polyclonal anti-b-catenin (H102) (Santa Cruz),
and rabbit polyclonal PRMT5 (Abcam), followed by washinger 3, 2015
(13 phosphate-buffered saline) and incubation with appropriate
Cy3 conjugated secondary antibodies. Nuclei of stained cells
were counterstained with 4,6-diamidino-2phenylindole (DAPI),
and coverslips were mounted on glass slides in Mowiol. Coverslips
were viewed on a Zeiss Axioplan2 fluorescence microscope, and
pictures were acquired with the Metamorph and AxioVision soft-
wares without further enhancement. For proximity ligation assays
(PLAs), PLA signals were automatically marked with threshold
images by a morphometric analysis module, and the number
of signals per cell was calculated by first marking nuclear
regions with threshold images of DAPI fluorescence and subse-
quently determining the number of PLA signals within as well
as outside nuclei. For quantification of nuclear puncta size in
Figures S4A and S4B, nuclear puncta were automatically marked
with threshold images by a morphometric analysis module, and
the area in pixels was calculated for every punctum in 20 cells
from three independent experiments. Pictures in Figure 4G were
processed with the 2D deconvolution module of the Metamorph
software. For quantification of Neuro2A differentiation in
Figure 5D, the percentage of cells showing neurites with a length
double that of the cell body diameter was calculated from
images of ten random coverslip fields from three independent
experiments.PLA
PLAwas carried out with the Duolink In Situ Starter Kit (Sigma) ac-
cording to the manufacturer’s instructions; mouse monoclonal
anti-ARID1B (Abcam) and rabbit polyclonal anti-b-catenin
(H102) (Santa Cruz) antibodies were used.Biochemistry
Western blotting and immunoprecipitations were performed as
described in Hadjihannas et al.33 The following primary anti-
bodies, rabbit polyclonal anti-ARID1B (Millipore), mouse mono-
clonal anti-ARID1B (Abcam), rabbit polyclonal anti-ARID1A
(Biomol, Hamburg, Germany), mouse monoclonal anti-Flag,
mouse monoclonal anti-b-actin (Sigma), rabbit monoclonal His-
tone H3 (D1H2) (Cell Signaling), mouse monoclonal anti-GFP
(Roche), rabbit polyclonal anti-b-catenin (H102) (Santa Cruz),
mouse monoclonal anti-T7 (Novagen-Millipore), and mouse
monoclonal anti-BRG1 (Santa Cruz), were used according to the
manufacturer’s instructions.Results
Differential Gene Expression between Individuals
with ID and Control Groups
To gain insight into ARID1B’s functions, we set out to
explore the effects of ARID1B loss-of-function mutations
on gene expression. To this end, we compared the expres-
sion profiles of individuals with ID and harboring ARID1B
mutations to the expression profiles of control groups by
whole-transcriptome analysis (RNA-Seq) of peripheral lym-
phocytes from fresh blood (Figures S1A and S1B; see Mate-
rials and Methods). It has been previously shown that, at
the trascriptome level, whole blood shares significant
gene-expression-profile similarities with multiple tissues,
including the CNS.34–37 Principal component analysis
identified distinct expression patterns between individualsThe Americanwith ID and control individuals (Figure 1A). Results were
validated by qRT-PCR in a randomly selected subset of
ten genes (Figure S1C). Prominent transcriptional changes
were observed in 452 genes (Figure 1B). Analysis with Inge-
nuity Systems’ IPA Software indicated significant changes
in a total of 39 biological processes and pathways (Table
S1). One of the most significantly altered pathways identi-
fied was the Wnt/b-catenin pathway. Although it is likely
that some of the other IPA-identified pathways might
be involved in the phenotype, we decided to concentrate
first on Wnt/b-catenin signaling, given that it is a well-
known developmental pathway whose significance in
neurogenesis and neuronal and brain development, as
well as in CNS defects, is well established. Therefore, we
further analyzed changes in Wnt/b-catenin target genes
and found significant upregulation of LEF1 (MIM:
153245), PTTG1(MIM: 604147), MYC (MIM: 190080),
TCF7 (MIM: 189908), PPARD (MIM: 600409), and NRCAM
(MIM: 601581), indicating increased Wnt/b-catenin
signaling in individuals with ID (Figure 1C). qRT-PCR for
three Wnt/b-catenin target genes, namely MYC, LEF1,
and TCF7, confirmed the above results (Figure 1D). These
findings indicated that ARID1B represses Wnt/b-catenin-
mediated transcription and that loss-of-function muta-
tions in ARID1B lead to derepression ofWnt/b-catenin
signaling.
ARID1B Specifically Represses Wnt/b-Catenin
Signaling Downstream of the b-Catenin Destruction
Complex
To investigate the role of ARID1B in Wnt/b-catenin
signaling, we made use of cell culture models exhibiting
low intensity of active Wnt/b-catenin signaling, HEK293T
and human osteosarcoma U2OS cells, and human colo-
rectal cancer cells exhibiting intrinsically aberrant Wnt/
b-catenin activity due to inactivating mutations in the
tumor suppressor APC (MIM: 611731) (SW480, DLD1) or
activating mutations in b-catenin (MIM: 116806) itself
(HCT116). We measured Wnt/b-catenin-dependent tran-
scription with a well-established luciferase reporter assay
(TOP/FOPFlash; see Materials and Methods). We knocked
down ARID1B in U2OS cells and confirmed knockdown
of ARID1B but not of the related ARID1A (MIM: 603024)
(Figure 2A). ARID1B knockdown in these cells led to a sig-
nificant upregulation of the Wnt/b-catenin target genes
MYC, LEF1, and TCF7, in support to the RNA-Seq studies
(Figure 2A). Knockdown of ARID1B in HEK293T cells,
which, like U2OS cells, exhibit low basal Wnt/b-catenin
signaling activity, increased Wnt/b-catenin-dependent
transcriptional reporters, similarly to knockdown of the
known negative regulators of the pathway Axin1 and APC
(Figure 2B and Figure S2A). This increase inWnt/b-catenin-
dependent transcription was also observed in the presence
ofWnt3A-conditionedmedia used to activate the pathway,
indicating that ARID1B regulates Wnt/b-catenin signaling
even under activating conditions (Figure 2B). Likewise,
siRNA-mediated knockdown via two different siRNAsJournal of Human Genetics 97, 445–456, September 3, 2015 447
Figure 1. Differential Gene Expression between ID-Affected Individuals and Control Groups
(A) Principal component analysis of RNA-Seq data showing the first two principal components (PC1 and PC2) of six ID-affected individ-
uals (red) and twelve control individuals (blue) from RPKM values of 24.364 genes.
(B) Heatmap showing differential expression patterns between ID-affected and control individuals with 452 genes with a fold change>2
and p value < 0.01 used in pathway analysis. Higher relative expression is indicated by darker hues.
(C) Mean normalized expression values (baseMean), fold change, and negative binomial p value for six Wnt/b-catenin target genes with
significant upregulation in ID-affected individuals in comparison to control individuals.
(D) Validation of RNA-Seq data with qRT-PCR in control and ID-affected individuals for three Wnt/b-catenin target genes: MYC, LEF1,
and TCF7. Relative expression shows the average values of twelve control individuals (set at a value of 1) and six ID-affected individuals.
Error bars represent SEM. Asterisks denote a p value of <0.05.specifically targeting ARID1B but not the related ARID1A
further increased Wnt/b-catenin activity in colorectal can-
cer cell lines DLD1, HCT116, and SW480 (Figure 2C and
Figures S2B and S2C). As expected, concurrent knockdown
of b-catenin completely abrogated the increase in Wnt/
b-catenin activity (Figure 2C).
Reciprocally, overexpression of T7-tagged human
ARID1B (hereafter referred to as ARID1B) inhibited Wnt/
b-catenin signaling activation by overexpression of Flag
b-catenin in both 293T and U2OS cells (Figure 2D and
Figure S2D). As expected, overexpression of Axin1 also in-
hibited Flag b-catenin-induced activity (Figure 2D). How-
ever, overexpression of ARID1B could not inhibit
transcriptional reporter activities for c-Jun or FoxO, either
with or without induction by overexpression of c-Jun or
FoxO3A, respectively, indicating that ARID1B specifically
represses Wnt/b-catenin-dependent transcription (Fig-
ure 2D). In addition, whereas overexpression of ARID1B
was also able to inhibit the high Wnt/b-catenin activity
in SW480 cells, it did not significantly alter c-Jun and
FoxO activities (Figure 2E and Figure S2E).448 The American Journal of Human Genetics 97, 445–456, SeptembNext, we determined whether ARID1B represses Wnt/
b-catenin-mediated transcription upstream or downstream
of the b-catenin destruction complex. For this we activated
Wnt/b-catenin signaling in HEK293T cells, which have a
functional b-catenin destruction complex, by overexpres-
sion of either GFP b-catenin or non-degradable b-catenin
harboring a substitution to Tyrosine at Ser33 (YFP S33Y)
and assessed the ability of ARID1B to inhibit the resultant
Wnt/b-catenin-dependent activation. As shown in Fig-
ure 2F, ARID1B was able to inhibit activation of the TOP/
FOPFlash reporters in response to both degradable and
non-degradable b-catenin to a similar extent. Accordingly,
no differences were observed in b-catenin protein amounts
between lymphoblastoid cell lines derived from ID-
affected individuals with ARID1B mutations and those
derived from control subjects (Figure 2G). Taken together,
these results show that ARID1B specifically represses Wnt/
b-catenin-dependent transcription downstream of the
b-catenin destruction complex and that loss of ARID1B
leads to upregulation of Wnt target genes in a b-catenin-
dependent fashion.er 3, 2015
Figure 2. ARID1B Represses Wnt/b-Catenin Signaling
(A) Western blotting for ARID1B and b-actin (left panels) and qRT-PCR for human ARID1B and ARID1A (right panel) from lysates and
with cDNAs, respectively, of U2OS cells transfected with indicated siRNAs. Molecular weights (kDa) are indicated on the left of
western-blotting panels. The bottom graph shows qRT-PCR for Wnt/b-catenin target genes MYC, LEF1, and TCF7 with cDNAs from
U2OS cells transfected with indicated siRNAs.
(B) Ratio of TOP/FOPFlash luciferase activity measuring b-catenin-dependent transcription in HEK293T cells transfected with indicated
siRNAs, in the absence (top panel) or presence (bottom panel) of Wnt3a-conditioned media (Wnt3A-CM) for 7 hr.
(C) Ratio of TOP/FOPFlash in DLD1 (top panel) and HCT116 (bottom panel) cells transfected with indicated combinations of
siRNAs.
(D) Luciferase reporter assays in HEK293T cells for Wnt/b-catenin-dependent (TOP/FOPFlash; left panel), c-Jun-dependent (pFR; middle
panel), and FoxO-dependent (8xDBE; right panel) reporters after transfection of indicated plasmid combinations. ARID1B refers to
T7-tagged ARID1B32 (also see Materials and Methods).
(E) Ratio of TOP/FOPFlash in SW480 cells transfected with indicated plasmids.
(F) Ratio of TOP/FOPFlash in 293T cells co-transfected with GFP b-catenin or a non-degradable b-catenin mutated on serine 33 (YFP
S33Y) together with ARID1B or an empty vector (Flag) as controls.
(legend continued on next page)
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Endogenous and Exogenous ARID1B Associates with
b-Catenin
To investigate the mechanism(s) by which ARID1B re-
presses b-catenin-dependent transcription, we employed
immunofluorescence microscopy in U2OS cells tran-
siently overexpressing ARID1B and/or GFP b-catenin.
When transfected alone, ARID1B localized exclusively in
the nucleus of transfected cells and exhibited a granular
yet diffuse localization, whereas GFP b-catenin showed
a diffuse cellular localization with a preference for the
nucleus and occasionally localized in small nuclear
puncta (Figure 3A). Strikingly, in a high percentage of cells
co-expressing both ARID1B and GFP b-catenin, we
observed the formation of well-defined nuclear puncta,
which corresponded to a full co-localization, suggesting
physical association between the two proteins (Figure 3A;
for quantification, also see Figure 4C). Therefore, we
investigated the existence of endogenous ARID1B/
b-catenin complexes in HCT116 cells, which express rela-
tively high amounts of both proteins. Indeed, immuno-
precipitation experiments showed that in nuclear lysates,
ARID1B was co-immunoprecipitated with b-catenin but
not with control IgG antibodies (Figure 3B). To visualize
endogenous ARID1B/b-catenin complexes, we carried
out PLAs with antibodies directed against ARID1B and
b-catenin.38 In our PLAs, primary ARID1B/b-catenin anti-
bodies raised in different species were used to stain
HCT116 cells and were subsequently labeled with
appropriate secondary antibodies conjugated with minus
and plus oligonucleotides, followed by ligation, amplifica-
tion, and incorporation of fluorescently labeled oligonu-
cleotides. Resultant fluorescent signals report a close
physical proximity between the two primary antibodies
and their antigens. We first verified that our antibodies
recognized their respective endogenous antigens in
HCT116 cells by standard immunofluorescence staining
(Figures S3A and S3B). Importantly, PLA for ARID1B/
b-catenin showed clear PLA signals in HCT116 cells as
assessed by fluorescent microscopy (Figure 3C). Auto-
mated signal detection from single-plane pictures showed
that, on average, there were around six signals per cell
and that over 70% of the signals occurred in the
nuclei of HCT116 cells (Figure 3D and Figure S3C). These
signals were specific for ARID1B/b-catenin because
efficient knockdown of either protein significantly
reduced PLA signals per cell (Figures 3C and 3D and Fig-
ures S3A and S3B). Taken together, these results clearly
demonstrate the existence of endogenous as well as
exogenous ARID1B/b-catenin complexes. Moreover, this
association seems to take place predominately in the
nucleus.(G) Western blotting for b-catenin and b-actin from lysates of lympho
ID-affected individuals as well as from colorectal cancer cells Caco-2
represent SEM from at least three independent experiments, each p
from quadruplicates. Single and double asterisks denote a p value of
t test, as compared to respective controls indicated in the main text.
450 The American Journal of Human Genetics 97, 445–456, SeptembARID1BAssociates with b-Catenin and RepressesWnt/
b-Catenin-Dependent Transcription through BRG1
Both ARID1B and b-catenin bind directly to the ATP-
dependent helicase BRG1 (encoded by SMARCA4 [MIM:
603254]), an enzymatic subunit of the BAF complex, albeit
to different regions.32,39 We observed that co-expression of
Flag BRG1 led to significantly larger exogenous ARID1B/
b-catenin nuclear puncta in U2OS cells, suggesting that
BRG1might mediate association between the two proteins
(Figure 3E and Figures S4A and S4B). We therefore assessed
the effect of BRG1 knockdown on the endogenous
ARID1B/b-catenin complexes in HCT116 by PLA. Efficient
knockdown of BRG1 significantly reduced ARID1B/b-cate-
nin PLA signals (Figures 3F and 3G and Figure S4C). Knock-
down of BRG1 had no effect on the protein amounts of
ARID1B or b-catenin, ruling out the possibility that
reduced ARID1B/b-catenin association was due to reduced
protein amounts (Figure S4C). Transfection of a siRNA spe-
cifically targeting ARID1A did not affect ARID1B/b-catenin
PLA signals, consistent with the fact that ARID1B and
ARID1A are part of mutually exclusive BAF remodeling
complexes (Figures 3F and 3G and Figure S4D).3 Impor-
tantly, knockdown of BRG1 alleviated the inhibitory effect
of ARID1B on Wnt/b-catenin signaling activation in
SW480 cells (Figure 3H). These results suggest that BRG1
mediates the association between b-catenin and an
ARID1B-based BAF complex to repress b-catenin-mediated
transcription.
Mutant ARID1B Proteins Show Compromised
Association with BRG1 and b-Catenin and Fail to
Repress Wnt/b-Catenin-Dependent Transcription
Mutations of ARID1B occurring in individuals with Coffin-
Siris syndrome and non-syndromic ID, as well as in
cancers, result in truncated ARID1B proteins.11 In ID, the
smallest truncation in ARID1B reported to date occurs
in an individual (individual 4 in Figure S1B) carrying
a de novo, heterozygous deletion (c.6463_6473del,
p.Ser2155Leufs*33) of ten nucleotides in exon 20 of
ARID1B (GenBank: NM_020732.3). This mutation deletes
only 30% of the highly conserved amino acid sequence
within the C terminus of ARID1B in the EDH2 domain
(Eld/Osa homology domain 2), which, intriguingly, has
been previously shown to mediate interaction with BRG1
(Figure S1A).32,39 This transcript is not subject to
nonsense-mediated decay given that it was readily detect-
able with RT-PCR from the RNA sample of the affected in-
dividual (Figure S5A). We generated an ARID1B expression
plasmid harboring this mutation (ARID1B-2188) and
found that the resultant protein was only weakly co-
immunoprecipitated with Flag BRG1 as compared toblastoid cell lines derived from three control indiviudals and three
. In all panels the cell line used is indicated at the top. Error bars
erformed with duplicates. In panel (A), error bars represent SEM
<0.05 and <0.01, respectively, calculated with unpaired Student’s
er 3, 2015
Figure 3. ARID1B Associates with b-Catenin in Nuclear Puncta and Represses Wnt/b-Catenin-Dependent Transcription
through BRG1
(A) Representative immunofluorescence pictures of U2OS cells expressing transfected ARID1B andGFP b-catenin, alone (rows 1 and 2) or
together (row3), stained with an antibody against ARID1B. Note that the antibody strongly recognizes overexpressed ARID1B as
compared to endogenous ARID1B in these cells.
(B) Western blotting (WB) for indicated endogenous proteins of lysates (INPUT) and IgG (control) or b-catenin immunoprecipitates (IP)
from HCT116 nuclei. Enrichment in nuclear proteins was confirmed by the presence of histone H3 (H3) and absence of a-tubulin.
Asterisk indicates heavy chains IgG, showing equal loading of IP reactions. Molecular weights (kDa) are indicated on the left of the
panels.
(C) Representative immunofluorescence pictures of proximity ligation assays (PLAs) for endogenous ARID1B and b-catenin in HCT116
cells transfected with indicated siRNAs.
(D) Quantification from experiments conducted in (C).
(E) Representative immunofluorescence pictures of U2OS cells co-expressing transfected ARID1B and GFP b-catenin in the absence or
presence of co-transfected Flag BRG1 (þ Flag BRG1) stained with an antibody against ARID1B.
(F) Immunofluorescence pictures of PLAs for endogenous ARID1B and b-catenin in HCT116 cells transfected with indicated siRNAs.
(legend continued on next page)
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wild-type ARID1B (Figure 4A). In addition to the ARID1B-
2188 mutant, we generated an ARID1B expression plasmid
harboring a mutation (c.5329A>T; p.Lys1777*) found also
in exon 20 in an individual with Coffin-Siris syndrome and
which, similarly to the majority of truncating ARID1Bmu-
tations found in cancers, deletes the EDH2 domain in its
entirety (ARID1B-1777) and assessed their co-localization
with GFP b-catenin in U2OS cells (see Figure S1A).Whereas
wild-type and mutant ARID1B proteins localized similarly
when expressed alone, the mutants exhibited significantly
reduced ability to form nuclear GFP b-catenin puncta as
compared to wild-type ARID1B (Figures 4B and 4C and
Figure S5B). As compared to ARID1B, both ARID1B-2188
and ARID1B-1777 showed reduced co-immunoprecipita-
tion with co-expressed b-catenin in HEK293T cells and
could not repress Wnt/b-catenin-dependent transcription
in SW480 cells (Figures 4D–4F). These data demonstrate
that ARID1Bmutations leading to partial or complete dele-
tion of the BRG1-binding domain compromise association
with b-catenin and ARID1B-mediated repression of Wnt/
b-catenin signaling.
ARID1B/b-Catenin Interaction Sites Are Enriched for
the Negative Regulator of Transcription PRMT5
The fact that ARID1B formed nuclear puncta with GFP
b-catenin and inhibited the GFP b-catenin-induced activa-
tion of reporters in U2OS indicated that this association is
repressive in nature (Figure 3A and Figure S2D). We there-
fore explored the composition of the ARID1B/b-catenin
puncta in U2OS cells. Using immunofluorescence staining
and 2D deconvolution microscopy, we found that PRMT5
(protein arginine N-methyltransferase 5), which promotes
a closed chromatin structure and was previously found
among ARID1B-interacting proteins, was highly enriched
in ARID1B/b-catenin nuclear puncta (Figure 4G).40,41 How-
ever, histone H3 acetylated on lysine 9 (acetylH3K9) or on
lysine 27 (acetylH3K27), histone H3 tri-methylated on
lysine 4 (H3K4me3), all of which are associated with
transcriptionally active chromatin, as well as histone H3
tri-methylated on lysine 9 (H3K9me3), histone H3 sym-
metrically dimethylated on arginine 8 (H3R8me2s), and
histone H4 symmetrically dimethylated on arginine 3
(H4R3me2s), all of which are associated with a repressive
chromatin state, were absent from ARID1B/b-catenin nu-
clear puncta (data not shown). This finding suggests that
either another histone modification(s) is responsible for
repression or that the chromatin architecture within or
surrounding these puncta is altered in an as-of-yet-
unknown way, and further studies are required to describe
the mechanism(s) involved.(G) Quantification from experiments conducted in (F).
(H) Ratio of TOP/FOPFlash in SW480 cells transfected with indicated
(siControl) or BRG1 (siBRG1). In panels (A) and (E), right columns sh
regions. In panels (D) and (G), n shows the number of nuclei analyz
differences from controls (siGFP), with unpaired Student’s t test, fro
SEM and single asterisks denote p< 0.05 for differences from contro
452 The American Journal of Human Genetics 97, 445–456, SeptembKnockdown of ARID1B Leads to Neurite Outgrowth in
a b-Catenin-Dependent Fashion
Substantial evidence from various model systems points to
an important role for Wnt signaling in neurite outgrowth
and axonal guidance.42 Previous studies have shown that
active forms of b-catenin promote neurite outgrowth in
human neuroblastoma lines and that b-catenin upregu-
lates the expression of neuronal cell adhesion molecules,
NRCAM and L1, that in turn stimulate neurite
outgrowth.43–45 Interestingly, NRCAM was one of the
genes that we found to be upregulated in individuals
with ARID1B-associated ID (Figure 1C). To determine
whether regulation of b-catenin-dependent transcription
by ARID1B is relevant to the function of Wnt signaling
in neurite outgrowth, we performed ARID1B knockdown
experiments in mouse neuroblastoma Neuro2A cells.
Efficient knockdown of ARID1B in these cells activated
b-catenin-dependent transcription (Figures 5A and 5B).
After knockdown of ARID1B, approximately 48% of
Neuro2A cells, versus 14% of control cells, exhibited pro-
nounced neurite outgrowth with neurites extending to
twice the length of the cell body diameter (Figures 5C
and 5D). Importantly, concurrent knockdown of b-catenin
blocked both the increase of b-catenin-dependent tran-
scription as well as the neurite outgrowth induced by
knockdown of ARID1B (Figure 5). These results indicate
that loss of ARID1B modulates neurite behavior in a b-cat-
enin-dependent fashion and is supportive of an ARID1B
function in brain and neuronal physiology.Discussion
Collectively, our findings illustrate that, in humans,
ARID1B is a repressor of the Wnt/b-catenin pathway and
that inactivation of ARID1B leads to elevated Wnt/b-cate-
nin-dependent transcription of target genes. Additionally,
regulation of b-catenin-mediated transcription by ARID1B
appears to control neurite outgrowth in mouse neuroblas-
toma cells, underscoring the physiological relevance of the
mechanism reported here.We propose that ARID1B associ-
ates with b-catenin via BRG1, thereby recruiting negative
regulators of transcription, such as PRMT5, to inhibit
Wnt/b-catenin-dependent transcription. Although it has
been previously shown that BRG1 acts as a co-activator
of Wnt/b-catenin signaling, our data support the notion
that combinatorial assembly of distinct BAF complexes
could determine their functional specificity, resulting in
either activation or repression of associated signaling path-
ways.11,22,46 It has been recently reported that loss of SNF5,plasmids in the presence of co-transfected siRNAs targeting GFP
ow merged pictures with DAPI and inlets show magnified nuclear
ed, error bars show SEM, and double asterisks denote p <0.01 for
m three independent experiments. In panel (H), error bars show
ls (Flag þ siControl) from at least three independent experiments.
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Figure 4. Mutant ARID1B Proteins Show Compromised Association with BRG1 and b-Catenin and Fail to Repress Wnt/b-Catenin-
Dependent Transcription
(A) Western blotting (WB) with indicated antibodies of lysates (INPUT) and Flag immunoprecipitates (IP) from 293T cells co-transfected
with Flag BRG1 and T7-tagged ARID1B or ARID1B-2188 mutant, as indicated.
(B) Representative immunofluorescence pictures of U2OS cells co-expressing GFP b-catenin together with ARID1B or mutants ARID1B-
2188 and ARID1B-1777 as indicated and stained with an antibody against ARID1B.
(C) Quantification from experiments conducted in (B).
(D) Western blotting (WB) with indicated antibodies of lysates (INPUT) and GFP immunoprecipitates (IP) from 293T cells co-transfected
with GFP b-catenin and T7-tagged ARID1B or ARID1B-2188 mutant, as indicated.
(E) Western blotting (WB) with indicated antibodies of lysates (INPUT) and b-catenin immunoprecipitates (IP) from 293T cells co-trans-
fected with Flag b-catenin and T7-tagged ARID1B or ARID1B-1777 mutant, as indicated. Molecular weights (kDa) in panels (A), (D), and
(E) are indicated on the left of the panels.
(F) Ratio of TOP/FOPFlash in SW480 cells transfected with indicated plasmids.
(G) Representative immunofluorescence pictures of U2OS cells after 2D image deconvolution co-expressing ARID1B and GFP b-catenin,
stained with antibodies against PRMT5. In panels (B) and (G), right columns showmerged pictures with DAPI and inlets showmagnified
nuclear regions. In panel (C), error bars show SEM from60 nuclei and double asterisks denote p< 0.01 for differences from controls, with
unpaired Student’s t test, from two independent experiments. In panel (F), error bars show SEM and (*) denotes p < 0.05 for differences
from control (Flag) from at least three independent experiments.
The American Journal of Human Genetics 97, 445–456, September 3, 2015 453
Figure 5. Knockdown of ARID1B in Neuro2A Cells Leads to Neu-
rite Outgrowth through b-Catenin
(A) Western blotting (WB) for ARID1B, b-catenin and b-actin from
lysates of mouse neuroblastoma Neuro2A cells transfected with
siRNAs against control, ARID1B or ARID1B, and b-catenin, as indi-
cated. Molecular weights (kDa) are indicated.
(B) Ratio of TOP/FOPFlash luciferase activity measuring b-catenin-
dependent transcription in Neuro2A cells transfected with indi-
cated siRNAs.
(C) Representative immunofluorescence pictures of Neuro2A cells
transfected with siRNAs against control or ARID1B and b-catenin
as indicated, stained for a-tubulin. Arrowheads point to neurites.
(D) Quantification of cells from (C) indicating the percentage of
cells exhibiting neurites with twice the length of the cell body.
n ¼ number of cells analyzed from three independent experi-
ments. Error bars in (B) and (D) represent SEM from two and three
independent experiments, respectively. Asterisks denote statistical
significance (p value of <0.05) as compared to respective controls
indicated in the main text, calculated with unpaired Student’s
t test.a BAF chromatin-remodeling subunit and tumor suppres-
sor, leads to derepression ofWnt target genes by decreasing
the ability of TCF4 (encoded by TCF7L2 [MIM: 602228]) to454 The American Journal of Human Genetics 97, 445–456, Septembbind and repress target genes.25 Although we do not
formally exclude the possibility that the mechanism for
derepression of Wnt-target genes after loss of ARID1B
might also involve decreased TCF4-associated repressive
activity, our results showing association between ARID1B
and b-catenin and the effects of ARID1B on TOP/FOPFlash
reporters are in favor of a b-catenin-dependent mecha-
nism. Furthermore, although we have shown that
knockdown of the related protein ARID1A does not inter-
fere with the association between ARID1B and b-catenin,
our preliminary data suggest that ARID1A itself can
also associate with GFP b-catenin in nuclear puncta, indi-
cating that ARID1A might operate in a similar fashion as
ARID1B in Wnt/b-catenin-dependent transcription (data
not shown).
It has beenpublished that ARID1A- andARID1B-contain-
ing chromatin-remodelling complexes are important for
cell cycle progression through regulation of MYC expres-
sion.30,47 As seen in our RNA-seq study, MYC, along with
other Wnt target genes, was upregulated in ID-affected
individuals and in ARID1B knockdown cells, suggesting
that ARID1B complexes might indeed impact cell cycle
progression. Taken together with previous work showing
that Wnt/b-catenin signaling is regulated during the cell
cycle, the present study raises the possibility that the
connection between ARID1 protein complexes and the
cell cycle is driven at least in part through the Wnt/b-cate-
nin pathway.33,48 In light of this possibility and while this
paper was under revision, Ruijtenberg and van den Heuvel
demonstrated that SWI/SNF remodeling complexes regu-
late lineage-specific cell cycle arrest during differentiation
by activating the expression of negative cell cycle regulators
but repressing positive regulators.49 This raises the question
as to how this complex is targeted to intended chromatin
locations for negative or positive cell cycle regulation.
Our finding that ARID1B can associate with, and inhibit,
b-catenin nuclear activity might shed light on how chro-
matin-remodeling complexes are targeted to specific loci.
In the past few years, several studies have reported
the presence of apparent loss-of-function mutations in
chromatin-remodeling factors in both developmental syn-
dromes associated with ID and in several human cancers.11
This ongoing identification of de novo mutations in ID
and somatic mutations in cancer of the very same factors
suggests an epigenetic convergence of the two pathologies.
Despite this convergence, the two pathologies are pheno-
typically disparate and current datasets do not indicate
that ID-affected individuals are at a greater risk for devel-
oping cancer, possibly due to the young age of mutation-
carrying individuals. Given that Wnt/b-catenin signaling
plays instrumental roles both during development and
carcinogenesis, its involvement after ARID1B loss of
function described in the present work could help us un-
derstand the molecular mechanisms underlying ID and
cancer. We speculate that the seemingly different patho-
logical outcomes of ARID1B mutations in individuals
with ID versus in those with cancer could either be dueer 3, 2015
to accompanying cooperative mutations in the latter and/
or due to tissue-specific deregulation of epigenetically regu-
lated pathways. Finally, our results offer a departure point
from which to further investigate the mechanisms by
which mutations in ARID1B, as well as in other chro-
matin-remodeling components, are involved in ID and
cancer through derepression of developmental and onco-
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